Protagonist Therapeutics Inc (PTGX) Stock Analysis

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $88.39
• Market Cap: $5.45B
• P/E Ratio: 131.97
• EPS: $0.66
• 52-Week High: $96.54
• 52-Week Low: $35.97

Market Sentiment

Protagonist Therapeutics Inc currently has a Neutral sentiment score of -0.01.

About Protagonist Therapeutics Inc

Protagonist Therapeutics, Inc. (PTGX) is a clinical-stage biopharmaceutical company focused on developing innovative peptide-based therapies aimed at addressing significant unmet medical needs, particularly in gastrointestinal disorders and hematological diseases. Leveraging its proprietary peptide technology platform, Protagonist is advancing a robust pipeline of therapeutic candidates designed to enhance patient outcomes. Based in Newark, California, the company is strategically positioned ...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for Protagonist Therapeutics Inc and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does PTGX pay dividends?

Protagonist Therapeutics Inc (PTGX) does not currently pay a regular dividend.

What is PTGX's P/E ratio?

Protagonist Therapeutics Inc has a price-to-earnings (P/E) ratio of 131.97.

What is PTGX's market cap?

Protagonist Therapeutics Inc (PTGX) has a market capitalization of $5.45B with a current stock price of $88.39.